Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Diagnostics & Testing
- Sub-Industry: N/A
- Symbol: NASDAQ:IOVA
- CUSIP: N/A
- Web: www.lbio.com
- Market Cap: $358.52 million
- Outstanding Shares: 62,351,000
- 50 Day Moving Avg: $6.24
- 200 Day Moving Avg: $6.86
- 52 Week Range: $4.90 - $9.58
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.23
- P/E Growth: 0.00
- Return on Equity: -10.07%
- Return on Assets: -9.81%
- Current Ratio: 27.74%
- Quick Ratio: 27.74%
- Average Volume: 412,202 shs.
- Beta: 4.5
Frequently Asked Questions for Lion Biotechnologies (NASDAQ:IOVA)
What is Lion Biotechnologies' stock symbol?
Lion Biotechnologies trades on the NASDAQ under the ticker symbol "IOVA."
How were Lion Biotechnologies' earnings last quarter?
Lion Biotechnologies, Inc. (NASDAQ:IOVA) announced its quarterly earnings data on Monday, May, 1st. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.05. View Lion Biotechnologies' Earnings History.
Where is Lion Biotechnologies' stock going? Where will Lion Biotechnologies' stock price be in 2017?
8 equities research analysts have issued 1 year price targets for Lion Biotechnologies' stock. Their predictions range from $11.00 to $20.00. On average, they anticipate Lion Biotechnologies' stock price to reach $15.17 in the next twelve months. View Analyst Ratings for Lion Biotechnologies.
What are analysts saying about Lion Biotechnologies stock?
Here are some recent quotes from research analysts about Lion Biotechnologies stock:
- 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (7/18/2017)
- 2. HC Wainwright analysts commented, "We project that one or more of these patients who achieved early PRs could transform to CRs with more follow up time as the infused TILs continue to act." (6/7/2017)
- 3. Jefferies Group LLC analysts commented, "LBIO reported 4Q16 financials and provided a pipeline update. LN-144 is on track with enrollment with data expected in 2017 at a medical congress. LBIO is also planning for add'l clinical trials in 2017 and has initiated head and neck indication with the cervical indication to initiate shortly. We think LBIO is making reasonable progress and look to the first LN-144 data readout for more details." (3/8/2017)
Who are some of Lion Biotechnologies' key competitors?
Some companies that are related to Lion Biotechnologies include La Jolla Pharmaceutical Company (LJPC), TG Therapeutics (TGTX), Crispr Theraptc (CRSP), Lantheus Holdings (LNTH), Vanda Pharmaceuticals (VNDA), Revance Therapeutics (RVNC), PTC Therapeutics (PTCT), Achaogen (AKAO), Coherus BioSciences (CHRS), Novadaq Technologies (NVDQ), Civitas Solutions (CIVI), Versartis (VSAR), Depomed (DEPO), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Meridian Bioscience (VIVO), Almost Family (AFAM) and AngioDynamics (ANGO).
Who are Lion Biotechnologies' key executives?
Lion Biotechnologies' management team includes the folowing people:
- Wayne Rothbaum, Interim Chairman of the Board
- Maria Fardis Ph.D., President, Chief Executive Officer
- Gregory T. Schiffman, Chief Financial Officer
- James G. Bender Ph.D., Vice President
- Iain D Dukes, Director
- Ryan D. Maynard, Director
- Sanford J. Hillsberg J.D., Independent Director
- Merrill A. McPeak USAF, Independent Director
- Jay Venkatesan M.D., Independent Director
Who owns Lion Biotechnologies stock?
Who bought Lion Biotechnologies stock? Who is buying Lion Biotechnologies stock?
How do I buy Lion Biotechnologies stock?
Shares of Lion Biotechnologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lion Biotechnologies' stock price today?
MarketBeat Community Rating for Lion Biotechnologies (NASDAQ IOVA)MarketBeat's community ratings are surveys of what our community members think about Lion Biotechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Lion Biotechnologies stock can currently be purchased for approximately $5.75.
Consensus Ratings for Lion Biotechnologies (NASDAQ:IOVA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||8 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$15.17 (163.77% upside)|
Analysts' Ratings History for Lion Biotechnologies (NASDAQ:IOVA)
(Data available from 7/28/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/6/2017||Cowen and Company||Reiterated Rating||Buy||Low|
|6/7/2017||HC Wainwright||Reiterated Rating||Buy||$16.00||Low|
|5/17/2017||Chardan Capital||Reiterated Rating||Buy||High|
|5/18/2017||FBR & Co||Reiterated Rating||Buy||High|
|5/18/2017||Jefferies Group LLC||Reiterated Rating||Buy||$11.00||Low|
|5/10/2017||Rodman & Renshaw||Initiated Coverage||Buy -> Buy||$13.00||Low|
|3/17/2017||Wells Fargo & Company||Initiated Coverage||Outperform -> Outperform||High|
|3/8/2017||Roth Capital||Set Price Target||Buy||$14.00||Low|
|6/6/2016||SunTrust Banks, Inc.||Downgrade||Buy -> Neutral||$37.00 -> $30.50||N/A|
|12/3/2015||Piper Jaffray Companies||Reiterated Rating||Buy||$21.00||N/A|
Earnings History for Lion Biotechnologies (NASDAQ:IOVA)Earnings History by Quarter for Lion Biotechnologies (NASDAQ IOVA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Lion Biotechnologies (NASDAQ:IOVA)
Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS
Dividend History for Lion Biotechnologies (NASDAQ:IOVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lion Biotechnologies (NASDAQ:IOVA)
Insider Ownership Percentage: 13.20%Insider Trades by Quarter for Lion Biotechnologies (NASDAQ:IOVA)
Institutional Ownership Percentage: 77.87%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/25/2016||Sanford Hillsberg||Director||Sell||54,000||$8.95||$483,300.00|| |
|8/22/2016||Sanford Hillsberg||Director||Sell||54,000||$9.11||$491,940.00|| |
|9/8/2015||Sanford Hillsberg||Director||Sell||32,500||$6.99||$227,175.00|| |
|5/6/2015||Sanford Hillsberg||Director||Sell||50,000||$10.00||$500,000.00|| |
|11/5/2013||Manish Singh||CEO||Buy||125,000||$2.00||$250,000.00|| |
Headline Trends for Lion Biotechnologies (NASDAQ:IOVA)
Latest Headlines for Lion Biotechnologies (NASDAQ:IOVA)
Lion Biotechnologies (IOVA) Chart for Friday, July, 28, 2017